Ann Thorac Med 2017 Oct-Dec;12(4):294-297
Department of Medical Specialties, Rheumatology Section, King Fahad Medical City, Riyadh, KSA.
There is increasing interest in rituximab (RTX) as an alternative to cyclophosphamide for the treatment of interstitial lung diseases (ILDs) associated with systemic sclerosis (SSc). However, no report has addressed its efficacy in Saudi patients with SSc-ILD. To assess the efficacy of RTX treatment in Saudi patients with SSc-ILD, hospital records were reviewed between 2013 and 2016. Read More